US 12,221,484 B2Granted

Anti-NMDA receptor antibodies and methods of use

AssigneeLankenau Institute for Medical Research

InventorsScott K. Dessain, Rashmi Sharma, Fetweh H. Al-Saleem

Life of this patent

Estimating the term…

Loading patent…

Abstract

A recombinant, synthetic or monoclonal human antibody or fragment thereof that binds to an N-methyl-D-aspartate Receptor (NMDAR) epitope, which antibody or fragment comprises at least one a heavy chain variable domain sequence encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NOs. 1, 3, or 5; or at least one a light chain variable domain sequence encoded by a nucleic acid sequence that is at least 80% identical to SEQ ID NOs: 2, 4, or 6. Assays for diagnosis of ANRE employ these NMDAR-binding antibodies, constructs, or epitope binding fragments. In one embodiment, multiple of the NMDAR-binding antibodies or fragments are used as controls because they bind non-overlapping target sequences on the NMDAR ATD.

Claims10

Dependent claims

A recombinant, synthetic, or monoclonal human antibody or antigen binding fragment thereof that specifically binds to an N-methyl-D-aspartate Receptor (NMDAR) protein comprising the amino acid sequence of SEQ ID NO:

7, said antibody or antigen binding fragment thereof comprising:
i. a heavy chain variable domain sequence comprising the amino acid sequence of SEQ ID NO:
10 and a light chain variable domain sequence comprising the amino acid sequence of SEQ ID NO:
11;
ii. a heavy chain variable domain sequence comprising the amino acid sequence of SEQ ID NO:
12 and a light chain variable domain sequence comprising the amino acid sequence of SEQ ID NO:
13;
or
iii. a heavy chain variable domain sequence comprising the amino acid sequence of SEQ ID NO:
14 and a light chain variable domain sequence comprising the amino acid sequence of SEQ ID NO:
15,
wherein the antibody or antigen binding fragment thereof is coupled covalently or non-covalently to a detectable label.

9 more elements

Dependencies are inferred from the claim text.

Facts

Application: 17/599,399Filed 8 Jun 2019 · us provisional application
Priority: 29 Mar 2019
Published: US 2022/0073611 A110 Mar 2022
Granted: 11 Feb 2025
Term ends: Not estimatedThe source records don’t support an estimate.

Classification14 codes

C07K 16/286
Against receptors, cell surface antigens or cell surface determinants: against neuromediator receptors, e.g. serotonin receptor, dopamine receptor
A61P 25/00
Drugs for disorders of the nervous system
G01N 33/564
Immunoassay; Biospecific binding assay; Materials therefor: for pre-existing immune complex or autoimmune disease , i.e. systemic lupus…
G01N 33/6872
Involving proteins, peptides or amino acids: intracellular protein regulatory factors and their receptors, e.g. including ion channels